Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,788.80
(
0.70%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.86
(
0.65%
)
Bitcoin
80,592.00
(
-0.57%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 140287

Friday, 06/28/2013 2:34:15 PM

Friday, June 28, 2013 2:34:15 PM

Post# of 257566

Biosimilar infliximab (Remicade)…Celltrion is partnered with HSP for this product.

Apparently, these companies are no longer partnered on Remicade insofar as they received distinct biosimilar approvals from the CHMP today (#msg-89473615). Unless Celltrion and HSP have some kind of profit-sharing agreement pertaining to both drugs, they would seem to be competitors rather than partners in this instance.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today